|
Tepel et al. [10]
|
07/00
|
65
|
NA
|
2.5
|
32.5
|
75
|
1
|
0.5 mg/dl 48 h
|
CT
|
600 mg tablet bid × 4
|
0.45% 1 ml/kg/h 12 h before, 12 h after
|
|
Diaz-Sandoval et al. [11]
|
02/02
|
73
|
80%
|
1.6
|
38.9
|
184
|
2
|
0.5 mg/dl or 25% 48 h
|
LHC
|
600 mg liquid in ginger ale bid × 4
|
0.45% 1 ml/kg/h 2–12 h before, 12 h after
|
|
Briguori et al. [12]
|
07/02
|
64
|
86%
|
1.5
|
37.8
|
197
|
1
|
25% 48 h
|
LHC and/or PA and/or PCI
|
600 mg tablet bid × 4
|
0.45% 1 ml/kg/h 12 h before, 12 h after
|
|
Vallero et al. [13]
|
09/02
|
62
|
NA
|
1.0
|
23.0
|
205
|
1
|
0.5 mg/dl or 33% 48 h
|
LHC and/or PCI
|
600 mg tablet bid × 4
|
0.45% 1 ml/kg/h 1–2 h before, 24 h after
|
|
Shyu et al. [14]
|
10/02
|
70
|
68%
|
2.8
|
63.5
|
117
|
1
|
0.5 mg/dl 48 h
|
LHC ± PCI
|
400 mg powder bid × 4
|
0.45% 1 ml/kg/h 12 h before, 12 h after
|
|
Allaqaband et al. [15]
|
11/02
|
70
|
NA
|
2.1
|
48.3
|
122
|
3
|
0.5 mg/dl 48 h
|
LHC ± PCI or PA + PCI
|
600 mg liquid in cola bid × 4
|
0.45% 1 ml/kg/h 12 h before, 12 h after
|
|
Durham et al. [16]
|
12/02
|
71
|
66%
|
2.3
|
48.1
|
81
|
3
|
0.5 mg/dl 48 h
|
LHC
|
1200 mg liquid in orange juice bid × 2
|
0.45% 1 ml/kg/h ≤ 12 h before, ≤ 12 h after
|
|
Kay et al. [17]
|
02/03
|
69
|
62%
|
1.3
|
37.5
|
125
|
5
|
25% 48 h
|
LHC and/or PCI
|
600 mg tablet bid × 4
|
0.9% 1 ml/kg/h 12 h before, 6 h after
|
|
Loutrianakis et al. [18]
|
03/03
|
67
|
NA
|
1.9
|
36.0
|
147
|
1
|
0.5 mg/dl 120–168 h
|
LHC
|
600 mg bid × 4
|
0.45% 1 ml/kg/h
|
|
Azmus et al. [19]
|
07/03
|
67
|
59%
|
1.3
|
49.6
|
126
|
5
|
0.5 mg/dl or 25% 24–48 h
|
LHC or PCI
|
600 mg powder in water bid × 5
|
0.9% 1 L pre, 1 L post, or none
|
|
Gomes et al. [20]
|
10/03
|
65
|
59%
|
1.3
|
51.9
|
103
|
4
|
0.5 mg/dl 48 h
|
LHC or PCI
|
600 mg bid × 4
|
0.9% 1 ml/kg/h 12 h before, 12 h after
|
|
Nguyen-Ho et al. [21]
|
11/03
|
70
|
NA
|
1.4
|
67.5
|
347
|
4
|
25% 48–72 h
|
LHC or PCI
|
2000 mg liquid in juice bid × 2 or 3
|
0.45% 75 ml/h ≥ 24 h from enroll
|
|
Efrati et al. [22]
|
12/03
|
67
|
90%
|
1.5
|
52.9
|
140
|
2
|
25% 24–96 h
|
LHC
|
1000 mg liquid in cola bid × 4
|
0.45% 1 ml/kg/h
|
|
El Mahmoud et al. [23]
|
12/03
|
67
|
81%
|
1.9
|
30.0
|
177
|
2
|
25% 24–48 h
|
LHC
|
600 mg orally bid × 2
|
0.9% 1 ml/kg/h
|
|
Kefer et al. [24]
|
12/03
|
62
|
77%
|
1.1
|
12.5
|
199
|
1
|
0.5 mg/dl or 25% 24 h
|
LHC and/or PCI
|
1200 mg in 0.9% saline IV over 60 min, 12 h pre 0 h post
|
0.9% 1 ml/kg/h
|
|
MacNeill et al. [25]
|
12/03
|
73
|
86%
|
1.9
|
46.5
|
110
|
4
|
25% 72 h
|
LHC ± PCI
|
600 mg liquid in juice/soda bid ×5
|
0.45% 1 ml/kg/h 12 h or 2 ml/kg/h 4 h before, 75 ml/h 12 h after
|
|
Oldemeyer et al. [26]
|
12/03
|
76
|
55%
|
1.6
|
44.9
|
131
|
2
|
0.5 mg/dl or 25% 48 h
|
LHC
|
1500 mg liquid in soda bid × 4
|
500 ml D5 20 ml/h 12 h before, 12 h after
|
|
Goldenberg et al. [27]
|
02/04
|
70
|
83%
|
2.0
|
43.9
|
116
|
5
|
0.5 mg/dl 48 h
|
LHC ± PCI
|
600 mg liquid in soda tid × 6
|
0.45% 1 ml/kg/h
|
|
Agrawal et al. [28]
|
04/04
|
63
|
68%
|
1.7
|
47.8
|
178
|
2
|
0.5 mg/dl or 25% 48 h
|
LHC and/or PCI
|
800/600/600 mg liquid in soda 12/2 h pre/6 h post
|
0.45% 1 ml/kg 12 h ± 250 ml bolus before, 12 h after
|
|
Fung et al. [29]
|
05/04
|
68
|
70%
|
2.3
|
52.8
|
128
|
3
|
0.5 mg/dl or 25% decrease in GFR 48 h
|
LHC or PCI ± PA
|
400 mg powder tid × 6
|
0.9% 100 ml/h 12 h before, 12 h after
|
|
Ochoa et al. [30]
|
06/04
|
71
|
43%
|
2.0
|
55.5
|
144
|
4
|
0.5 mg/dl or 25% 48 h
|
LHC and/or PCI
|
1000 mg liquid in diet cola bid × 2
|
0.9% 150 ml/h, ≥ 500 ml 12 h before, ≥ 1000 24 h after
|
|
Webb et al. [31]
|
09/04
|
70
|
NA
|
1.7
|
34.9
|
120
|
5
|
0.5 mg/dl 48–192 h
|
LHC or PCI ± PA
|
500 mg in D5NS IV for 15 min, 1 h pre
|
0.9% 200 ml before, 1.5 ml/kg/h 6 h or discharge (<6 h) after
|
